http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Molecular targets in protein misfolding and neurodegenerative disease
1 online resource (314 pages) : illustrations (some color)
Aimed at "drug discoverers"--I.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc
Cover; Title Page; Copyright Page; Dedication; Contents; Abbreviations; Chapter 1 -- Protein Misfolding, Neurodegeneration and Tau; 1.1 -- The neurodegeneration scenario; 1.2 -- Protein folding: physiological benefits and pathological consequences; 1.3 -- Tau: An intrinsically disordered, flexible, and aggregation-prone protein; 1.4 -- Tauopathies: Aggregation-prone tau in neurodegenerative disease (NDD); 1.4.1 -- Class 0 Tauopathies; 1.4.2 -- Class I Tauopathies; 1.4.3 -- Class II Tauopathies; 1.4.4 -- Class III Tauopathies; 1.4.5 -- Class IV Tauopathies; 1.4.6 -- Tau Mutations; References.
Chapter 2 -- Targeting the Protein Quality Control (PQC) Machinery2.1 -- Molecular chaperones, PQC, and neurodegeneration; 2.2 -- Molecular targets; 2.2.1 -- Hsp27; 2.2.2 -- Hsp70; 2.2.3 -- Hsp90; 2.3 -- Disease-modifying compounds; References; Chapter 3 -- Proteasomal Degradation of Soluble, Misfolded Proteins; 3.1 -- UPS-mediated degradation of misfolded proteins; 3.2 -- UPS-mediated degradation of misfolded proteins in NDDs; 3.3 -- UPS-targets; 3.3.1 -- CHIP; 3.3.2 -- USP14; 3.4 -- Disease-modifying compounds; References; Chapter 4 -- Unselective Disposal of Cellular Aggregates.
4.1 -- Autophagy-mediated degradation of protein aggregates4.2 -- Autophagy-mediated degradation of protein aggregates in NDDs; 4.3 -- Macroautophagy-targets; 4.3.1 -- mTORC1; 4.4 -- Disease-modifying compounds; References; Chapter 5 -- Selective Disposal of Insoluble Protein Aggregates; 5.1 -- Aggrephagy-mediated degradation of protein aggregates; 5.2 -- Selective autophagy-mediated degradation of protein aggregates in NDDs; 5.3 -- Selective autophagy-targets; 5.3.1 -- p62; 5.3.2 -- HDAC6; 5.4 -- Disease-modifying compounds; References; Chapter 6 -- Assembly and Disassembly of Protein Aggregates.
6.1 -- Introduction6.2 -- Disordered protein aggregates and ordered amyloid fibrils; 6.2.1 -- The Target: Interfering with (Neuro)toxic Tau Species in the Aggregation Process; 6.3 -- Chaperone-driven disaggregation of protein aggregates; 6.3.1 -- The Target: Hsp110; 6.4 -- Disease-modifying compounds; References; Conclusions; Index.
Includes bibliographical references at the end of each chapters and index.